Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ventilator Associated Pneumonia
- Sponsor
- Semmelweis University
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- 28-day all-cause mortality
- Last Updated
- 5 years ago
Overview
Brief Summary
The aim of this study is to determine the risk factors for development of ventilator-associated pneumonia (VAP) and to identify the prognostic factors of VAP among Coronavirus Disease 2019 (CoViD-19) patients. We hypothesized that CoViD-19 serves as a high risk factor for the development of VAP and it affects clinical outcome measures negatively.
Detailed Description
Coronavirus Disease 2019 (CoViD-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a pandemic affecting thousands of individuals worldwide. A considerable proportion of CoViD-19 patients require admission to the intensive care unit (ICU), although limited data are available on their clinical characteristics and course. The results of retrospective studies indicate older age, presence of comorbidies and secondary infections as predictors of mortality among this population. Further evaluation regarding ICU clinical course and predictors of mortality is needed. The aim of this study is to determine the risk factors for development of VAP and to identify the prognostic factors of VAP among CoViD-19 patients.
Investigators
Zsolt Iványi
Associate Professor
Semmelweis University
Eligibility Criteria
Inclusion Criteria
- •Critically ill individuals diagnosed with PCR confirmed CoViD-19 disease
- •Started mechanical ventilation for \> 48 hours
- •Informed consent signed by the patient or authorised representative
Exclusion Criteria
- •Participation in an interventional trial aiming nosocomial infections
- •refused informed consent
Outcomes
Primary Outcomes
28-day all-cause mortality
Time Frame: at study completion, anticipated 5 months
Secondary Outcomes
- ICU length-of-stay(average time frame expected 3-4 weeks)
- Days of mechanical ventilation(average time frame expected 2-3 weeks)
- Antibiotic utilization(average time frame expected 3-4 weeks (at discharge from ICU))
- Ventilator-associated pneumonia rate(at study completion, anticipated 5 months)